WuXi Biologics
https://www.wuxibiologics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From WuXi Biologics
Can BIOSECURE Maintain Its Virality In The TikTok Era?
With the sheen of inevitability now scuffed off the BIOSECURE Act, diplomatic efforts to reduce US dependence on Chinese APIs are increasing in prominence. And the power of the legislation itself could be determined by litigation about a video app.
China Biotech CEO Interview: Starting A CNS Venture In An Economic Downturn
From Wyeth/Pfizer to Jiangsu Hengrui to IMab to starting her own biotech, Joan Huaqiong Shen has seen many ups and downs of drug development in China. She sat down with Scrip on the sidelines of the recent DIA China meeting to discuss her latest startup devoted to novel small molecules to treat schizophrenia and epilepsy and a gene therapy for ALS.
BIOSECURE Act Diluted Significantly, But China Plus Strategy Still Accelerating: Strides MD
A time extension to US companies to shift business away from a few Chinese firms under the proposed BIOSECURE Act has disappointed the Strides MD. However, the China plus strategy continues to drive business and capacity expansion for auto-injectors required by GLP-1 customers is expected
China, EU Regulators Highlight Innovation, Access And Collaboration As Key Policy Aims
Former and incumbent regulatory officials from China and the European Union highlighted the need for supportive regulatory policies for the innovative drug sector at the recent DIA China annual meeting.
Company Information
- Industry
- Contract Research Organization-CRO
- Pharmaceuticals
- Services
-
Biotechnology
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice